Immunoglobulin E (IgE) is a type of antibody (or immunoglobulin (Ig) "isotype") that has only been found in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). IgE's main function is immunity to parasites such as helminths like Schistosoma mansoni, Trichinella spiralis, and Fasciola hepatica. IgE is utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum. IgE may have evolved as a last line of defense to protect against venoms.
IgE also has an essential role in type I hypersensitivity, which manifests in various allergic diseases, such as allergic asthma, most types of sinusitis, allergic rhinitis, food allergies, and specific types of chronic urticaria and atopic dermatitis. IgE also plays a pivotal role in responses to allergens, such as: anaphylactic reactions to drugs, bee stings, and antigen preparations used in desensitization immunotherapy.
Although IgE is typically the least abundant isotype—blood serum IgE levels in a normal ("non-atopic") individual are only 0.05% of the Ig concentration, compared to 75% for the IgGs at 10 mg/ml, which are the isotypes responsible for most of the classical adaptive immune response—it is capable of triggering the most powerful inflammatory reactions.
IgE was simultaneously discovered in 1966 and 1967 by two independent groups: Kimishige Ishizaka and his wife Teruko Ishizaka at the Children's Asthma Research Institute and Hospital in Denver, Colorado, and by S.G.O Johansson and Hans Bennich in Uppsala, Sweden. Their joint paper was published in April 1969.
IgE primes the IgE-mediated allergic response by binding to Fc receptors found on the surface of mast cells and basophils. Fc receptors are also found on eosinophils, monocytes, macrophages and platelets in humans. There are two types of Fcε receptors:
- FcεRI (type I Fcε receptor), the high-affinity IgE receptor
- FcεRII (type II Fcε receptor), also known as CD23, the low-affinity IgE receptor
IgE can upregulate the expression of both types of Fcε receptors. FcεRI is expressed on mast cells, basophils, and the antigen-presenting dendritic cells in both mice and humans. Binding of antigens to IgE already bound by the FcεRI on mast cells causes cross-linking of the bound IgE and the aggregation of the underlying FcεRI, leading to degranulation (the release of mediators from the cells) and the secretion of several types of type 2 cytokines like IL-3 and Stem Cell Factor (SCF) which both help the mast cells survive and accumulate in tissue, IL-4, IL-5 and IL-13 as well as IL-33 which in turn activate group 2-innate lymphoid cells (ILC2, or natural helper cells). Basophils, which share a common haemopoietic progenitor with mast cells, upon the cross-linking of their surface bound IgE by antigens, also release type 2 cytokines like interleukin-4 (IL-4) and interleukin-13 (IL-13) and other inflammatory mediators. The low-affinity receptor (FcεRII) is always expressed on B cells; but IL-4 can induce its expression on the surfaces of macrophages, eosinophils, platelets, and some T cells.
There has been an accumulating evidence in the past decade on the physiological role of IgE: this isotype has co-evolved with basophils and mast cells in the defence against parasites like helminths (like Schistosoma) but may be also effective in bacterial infections. Epidemiological research shows that IgE level is increased when infected by Schistosoma mansoni, Necator americanus, and nematodes in humans. It is most likely beneficial in removal of hookworms from the lung.
Toxin hypothesis of allergic disease
In 1981 Margie Profet suggested that allergic reactions have evolved as a last line of defense to protect against venoms. Although controversial at the time, new work supports some of Profet’s thoughts on the adaptive role of allergies as a defense against noxious toxins.
In 2013 it emerged that IgE-antibodies play an essential role in acquired resistance to honey bee and Russell's viper venoms. The authors conclude that "a small dose of bee venom conferred immunity to a much larger, fatal dose" and "this kind of venom-specific, IgE-associated, adaptive immune response developed, at least in evolutionary terms, to protect the host against potentially toxic amounts of venom, such as would happen if the animal encountered a whole nest of bees, or in the event of a snakebite". The major allergen of bee venom (phospholipase A2) induces a Th2 immune responses, associated with production of IgE antibodies, which may "increase the resistance of mice to challenge with potentially lethal doses".
Although it is not yet well understood, IgE may play an important role in the immune system's recognition of cancer, in which the stimulation of a strong cytotoxic response against cells displaying only small amounts of early cancer markers would be beneficial. If this were the case, anti-IgE treatments such as omalizumab (for allergies) might have some undesirable side effects. However, a recent study, which was performed based on pooled analysis using comprehensive data from 67 phase I to IV clinical trials of omalizumab in various indications, concluded that a causal relationship between omalizumab therapy and malignancy is unlikely.
Role in disease
Atopic individuals can have up to ten times the normal level of IgE in their blood (as do sufferers of hyper-IgE syndrome). However, this may not be a requirement for symptoms to occur as has been seen in asthmatics with normal IgE levels in their blood—recent research has shown that IgE production can occur locally in the nasal mucosa.
IgE that can specifically recognise an allergen (typically this is a protein, such as dust mite Der p 1, cat Fel d 1, grass or ragweed pollen, etc.) has a unique long-lived interaction with its high-affinity receptor FcεRI so that basophils and mast cells, capable of mediating inflammatory reactions, become "primed", ready to release chemicals like histamine, leukotrienes, and certain interleukins. These chemicals cause many of the symptoms we associate with allergy, such as airway constriction in asthma, local inflammation in eczema, increased mucus secretion in allergic rhinitis, and increased vascular permeability, it is presumed, to allow other immune cells to gain access to tissues, but which can lead to a potentially fatal drop in blood pressure as in anaphylaxis.
IgE is known to be elevated in various autoimmune disorders such as SLE, rheumatoid arthritis (RA), and psoriasis, and is theorized to be of pathogenetic importance in SLE and RA by eliciting a hypersensitivity reaction.
Regulation of IgE levels through control of B cell differentiation to antibody-secreting plasma cells is thought to involve the "low-affinity" receptor FcεRII, or CD23. CD23 may also allow facilitated antigen presentation, an IgE-dependent mechanism whereby B cells expressing CD23 are able to present allergen to (and stimulate) specific T helper cells, causing the perpetuation of a Th2 response, one of the hallmarks of which is the production of more antibodies.
Role in diagnosis
Diagnosis of allergy is most often done by reviewing a person's medical history and finding a positive result for the presence of allergen specific IgE when conducting a skin or blood test. Specific IgE testing is the proven test for allergy detection; evidence does not show that indiscriminate IgE testing or testing for immunoglobulin G (IgG) can support allergy diagnosis.
Drugs targeting the IgE pathway
Currently, allergic diseases and asthma are usually treated with one or more of the following drugs: (1) antihistamines and antileukotrienes, which antagonize the inflammatory mediators histamine and leukotrienes, (2) local or systemic (oral or injectable) corticosteroids, which suppress a broad spectrum of inflammatory mechanisms, (3) short or long-acting bronchodilators, which relax smooth muscle of constricted airway in asthma, or (4) mast cell stabilizers, which inhibit the degranulation of mast cells that is normally triggered by IgE-binding at FcεRI. Long-term uses of systemic corticosteroids are known to cause many serious side effects and are advisable to avoid, if alternative therapies are available.
IgE, the IgE synthesis pathway, and the IgE-mediated allergic/inflammatory pathway are all important targets in intervening with the pathological processes of allergy, asthma, and other IgE-mediated diseases. The B lymphocyte differentiation and maturation pathway that eventually generate IgE-secreting plasma cells go through the intermediate steps of IgE-expressing B lymphoblasts and involves the interaction with IgE-expressing memory B cells. Tanox, a biotech company based in Houston, Texas, proposed in 1987 that by targeting membrane-bound IgE (mIgE) on B lymphoblast and memory B cells, those cells can be lysed or down-regulated, thus achieving the inhibition of the production of antigen-specific IgE and hence a shift of immune balance toward non-IgE mechanisms. Two approaches targeting the IgE pathway were evolved and both are in active development. In the first approach, the anti-IgE antibody drug omalizumab (trade name Xolair) recognises IgE not bound to its receptors and is used to neutralise or mop-up existing IgE and prevent it from binding to the receptors on mast cells and basophils. Xolair has been approved in many countries for treating severe, persistent allergic asthma. It has also been approved in March 2014 in the European Union and the U. S. for treating chronic spontaneous urticaria, which cannot be adequately treated with H1-antihistamines. In the second approach, antibodies specific for a domain of 52 amino acid residues, referred to as CεmX or M1’ (M1 prime), present only on human mIgE on B cells and not on free, soluble IgE, have been prepared and are under clinical development for the treatment of allergy and asthma. An anti-M1’ humanized antibody, quilizumab, is in phase IIb clinical trial.
In 2002, researchers at The Randall Division of Cell and Molecular Biophysics determined the structure of IgE. Understanding of this structure (which is atypical of other isotypes in that it is highly bent and asymmetric) and of the interaction of IgE with receptor FcεRI will enable development of a new generation of allergy drugs that seek to interfere with the IgE-receptor interaction. It may be possible to design treatments cheaper than monoclonal antibodies (for instance, small molecule drugs) that use a similar approach to inhibit binding of IgE to its receptor.
- "Antibody structure". Archived from the original on September 6, 2008.
- Erb KJ (May 2007). "Helminths, allergic disorders and IgE-mediated immune responses: where do we stand?". European Journal of Immunology. 37 (5): 1170–3. doi:10.1002/eji.200737314. PMID 17447233. S2CID 24519249.
- Fitzsimmons CM, McBeath R, Joseph S, Jones FM, Walter K, Hoffmann KF, et al. (2007). "Factors affecting human IgE and IgG responses to allergen-like Schistosoma mansoni antigens: Molecular structure and patterns of in vivo exposure". International Archives of Allergy and Immunology. 142 (1): 40–50. doi:10.1159/000095997. PMID 17019080. S2CID 16676316.
- Watanabe N, Bruschi F, Korenaga M (April 2005). "IgE: a question of protective immunity in Trichinella spiralis infection". Trends in Parasitology. 21 (4): 175–8. doi:10.1016/j.pt.2005.02.010. PMID 15780839.
- Pfister K, Turner K, Currie A, Hall E, Jarrett EE (November 1983). "IgE production in rat fascioliasis". Parasite Immunology. 5 (6): 587–93. doi:10.1111/j.1365-3024.1983.tb00775.x. PMID 6657297. S2CID 1530964.
- Duarte J, Deshpande P, Guiyedi V, Mécheri S, Fesel C, Cazenave PA, et al. (January 2007). "Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status". Malaria Journal. 6: 1. doi:10.1186/1475-2875-6-1. PMC 1781948. PMID 17204149.
- Profet M (March 1991). "The function of allergy: immunological defense against toxins". The Quarterly Review of Biology. 66 (1): 23–62. doi:10.1086/417049. PMID 2052671. S2CID 5648170.
- Palm NW, Rosenstein RK, Medzhitov R (April 2012). "Allergic host defences". Nature. 484 (7395): 465–72. Bibcode:2012Natur.484..465P. doi:10.1038/nature11047. PMC 3596087. PMID 22538607.
- Marichal T, Starkl P, Reber LL, Kalesnikoff J, Oettgen HC, Tsai M, et al. (November 2013). "A beneficial role for immunoglobulin E in host defense against honeybee venom". Immunity. 39 (5): 963–75. doi:10.1016/j.immuni.2013.10.005. PMC 4164235. PMID 24210352.
- Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, et al. (2003). "The biology of IGE and the basis of allergic disease". Annual Review of Immunology. 21: 579–628. doi:10.1146/annurev.immunol.21.120601.141103. PMID 12500981.
- Winter WE, Hardt NS, Fuhrman S (September 2000). "Immunoglobulin E: importance in parasitic infections and hypersensitivity responses". Archives of Pathology & Laboratory Medicine. 124 (9): 1382–5. doi:10.1043/0003-9985(2000)124<1382:IE>2.0.CO;2 (inactive 2020-11-13). PMID 10975945.CS1 maint: DOI inactive as of November 2020 (link)
- Stanworth DR (February 1993). "The discovery of IgE". Allergy. 48 (2): 67–71. doi:10.1111/j.1398-9995.1993.tb00687.x. PMID 8457034. S2CID 36262710.
- Ishizaka K, Ishizaka T, Hornbrook MM (July 1966). "Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity". Journal of Immunology. 97 (1): 75–85. PMID 4162440.
- Johansson SG, Bennich H (October 1967). "Immunological studies of an atypical (myeloma) immunoglobulin". Immunology. 13 (4): 381–94. PMC 1409218. PMID 4168094.
- Ishizaka T, Ishizaka K, Johansson SG, Bennich H (April 1969). "Histamine release from human leukocytes by anti-gamma E antibodies". Journal of Immunology. 102 (4): 884–92. PMID 4181251. Retrieved 2016-02-29.
- Ewart MA, Ozanne BW, Cushley W (May 2002). "The CD23a and CD23b proximal promoters display different sensitivities to exogenous stimuli in B lymphocytes". Genes and Immunity. 3 (3): 158–64. doi:10.1038/sj.gene.6363848. PMID 12070780.
- Novak N, Kraft S, Bieber T (December 2001). "IgE receptors". Current Opinion in Immunology. 13 (6): 721–6. doi:10.1016/s0952-7915(01)00285-0. PMID 11677096.
- Rihet P, Demeure CE, Bourgois A, Prata A, Dessein AJ (November 1991). "Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels". European Journal of Immunology. 21 (11): 2679–86. doi:10.1002/eji.1830211106. PMID 1936116. S2CID 1103861.
- Pritchard DI, Quinnell RJ, Walsh EA (February 1995). "Immunity in humans to Necator americanus: IgE, parasite weight and fecundity". Parasite Immunology. 17 (2): 71–5. doi:10.1111/j.1365-3024.1995.tb00968.x. PMID 7761110. S2CID 41222700.
- Turner JD, et al. (June 2005). "Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection". Microbes and Infection. 7 (7–8): 990–6. doi:10.1016/j.micinf.2005.03.036. PMID 15961339.
- Starkl P, Marichal T, Gaudenzio N, Reber LL, Sibilano R, Tsai M, Galli SJ (January 2016). "IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity". The Journal of Allergy and Clinical Immunology. 137 (1): 246–257.e11. doi:10.1016/j.jaci.2015.08.005. PMC 4715494. PMID 26410782.
- Sharlach, Molly (24 October 2013). "Bee sting allergy could be a defense response gone haywire, scientists say". Stanford Medicine News Center. Retrieved 20 November 2019.
- Foley, James A. (25 October 2013). "Severe Allergies to Bee Stings may be Malfunctioning Evolutionary Response". Nature World News.
- Tsai M, Starkl P, Marichal T, Galli SJ (October 2015). "Testing the 'toxin hypothesis of allergy': mast cells, IgE, and innate and acquired immune responses to venoms". Current Opinion in Immunology. 36: 80–7. doi:10.1016/j.coi.2015.07.001. PMC 4593748. PMID 26210895.
- Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et al. (April 2003). "Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells". European Journal of Immunology. 33 (4): 1030–40. doi:10.1002/eji.200323185. PMID 12672069. S2CID 29495137.
- Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J (April 2012). "Omalizumab and the risk of malignancy: results from a pooled analysis". The Journal of Allergy and Clinical Immunology. 129 (4): 983–9.e6. doi:10.1016/j.jaci.2012.01.033. PMID 22365654.
- Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, et al. (April 2005). "Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis". Journal of Immunology. 174 (8): 5024–32. doi:10.4049/jimmunol.174.8.5024. PMID 15814733.
- Permin H, Wiik A (October 1978). "The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus". Acta Pathologica et Microbiologica Scandinavica, Section C. 86C (5): 245–9. doi:10.1111/j.1699-0463.1978.tb02587.x. PMID 309705.
- Elkayam O, Tamir R, Pick AI, Wysenbeek A (January 1995). "Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus". Allergy. 50 (1): 94–6. PMID 7741196.
- Conrad DH, Ford JW, Sturgill JL, Gibb DR (September 2007). "CD23: an overlooked regulator of allergic disease". Current Allergy and Asthma Reports. 7 (5): 331–7. doi:10.1007/s11882-007-0050-y. PMID 17697638. S2CID 24816595.
- Holm J, Willumsen N, Würtzen PA, Christensen LH, Lund K (April 2011). "Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity". The Journal of Allergy and Clinical Immunology. 127 (4): 1029–37. doi:10.1016/j.jaci.2011.01.062. PMID 21377718.
- Cox L, Williams B, Sicherer S, Oppenheimer J, Sher L, Hamilton R, Golden D (December 2008). "Pearls and pitfalls of allergy diagnostic testing: report from the American College of Allergy, Asthma and Immunology/American Academy of Allergy, Asthma and Immunology Specific IgE Test Task Force". Annals of Allergy, Asthma & Immunology. 101 (6): 580–92. doi:10.1016/S1081-1206(10)60220-7. PMID 19119701.
- American Academy of Allergy, Asthma, and Immunology. "Five Things Physicians and Patients Should Question" (PDF). Choosing Wisely: An Initiative of the ABIM Foundation. Archived from the original (PDF) on November 3, 2012. Retrieved August 14, 2012.CS1 maint: multiple names: authors list (link)
- Chang TW, Wu PC, Hsu CL, Hung AF (2007). Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv. Immunol. Advances in Immunology. 93. pp. 63–119. doi:10.1016/S0065-2776(06)93002-8. ISBN 9780123737076. PMID 17383539.
- "Novartis announces Xolair® approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines". Novartis. 2014-03-06. Archived from the original on 2014-12-18. Retrieved 2014-12-04.
- "Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria (CIU)". Novartis. 2014-03-21. Archived from the original on 2014-12-03. Retrieved 2014-12-04.
- Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, et al. (February 2010). "Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells". Journal of Immunology. 184 (4): 1748–56. doi:10.4049/jimmunol.0902437. PMID 20083663.
- Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, et al. (June 2010). "Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice". The Journal of Clinical Investigation. 120 (6): 2218–29. doi:10.1172/JCI40141. PMC 2877936. PMID 20458139.
- "MEMP1972A". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 2014-12-04.
- Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, et al. (July 2014). "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production". Science Translational Medicine. 6 (243): 243ra85. doi:10.1126/scitranslmed.3008961. PMID 24990880. S2CID 41593528.
- Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M, et al. (July 2002). "The crystal structure of IgE Fc reveals an asymmetrically bent conformation". Nature Immunology. 3 (7): 681–6. doi:10.1038/ni811. PMID 12068291. S2CID 32347451.